Close Menu
Home › PredictImmune Receives £4.3M From Wellcome Trust for Crohn's Biomarker Study

PredictImmune Receives £4.3M From Wellcome Trust for Crohn's Biomarker Study

Apr 30, 2018
|
staff reporter

NEW YORK (GenomeWeb) – PredictImmune announced today that it has received £4.3 million ($5.9 million) from the Wellcome Trust to clinically evaluate its biomarker test for Crohn's disease.

PredictImmune's test — which the company expects to commercialize in the US and Europe next year — is designed to measure genetic markers in whole-blood samples in order to predict which Crohn's disease patients are likely to experience a severe, relapsing form of the disease to help personalize their treatment.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
16
Featured Webinar

Using Next-Generation Sequencing to Detect Genomic Mutations in Hematologic Malignancies

Sponsored by
ArcherDX

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.

Oct
03
Featured Webinar

Streamlined and High-Precision Cancer Analysis Using an Automated NGS Workflow in the Reference Lab Setting

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In Molecular Diagnostics

  1. USPSTF Formalizes Slightly Expanded BRCA Screening Recommendations

  2. FDA Stepping Up Actions Against PGx Testing, Forcing Some Labs to Stop Reporting Drug Information

  3. OpGen Progresses on Pipeline of Highly Multiplexed Drug-Resistant Bacteria Tests

    Premium

  4. Genomind, NeuroFlow Collaborate to Provide Genetic Testing-Based Mental Health Services

  5. Quantabio Continues Newborn Screening Expansion as Tech Adopted by Wisconsin State Program

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.